XOMA Corporation (Nasdaq: XOMA) announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes. XMetA is the first antibody specific for the insulin receptor shown to correct hyperglycemia in a mouse model ofdiabetes. Results of a...
Search This Blog
-----------------------------------------------------------------------------------------------------------------------------------------------------------------
Showing posts with label glycemic control. Show all posts
Showing posts with label glycemic control. Show all posts